Stock market today: S&P 500 extends monthly win streak despite Nvidia-led stumble
PALO ALTO, Calif. - Guardant Health , Inc. (NASDAQ:GH), a precision oncology company, reported fourth-quarter 2024 results that exceeded analyst expectations, while also raising its revenue outlook for 2025. Despite the positive results, the company’s shares dipped 1.9% in after-hours trading.
The company reported Q4 revenue of $201.8 million, surpassing the analyst consensus of $186.78 million and marking a 30% increase YoY. Adjusted earnings per share came in at -$0.62, beating estimates of -$0.78.
Guardant Health’s precision oncology revenue grew 30% to $184.6 million, driven by a 24% increase in clinical test volume and a 16% rise in biopharma tests. The company reported approximately 57,300 oncology clinical tests and 11,050 biopharma tests during the quarter.
For the full year 2024, Guardant Health’s total revenue reached $739.0 million, up 31% from the previous year. The company attributed this growth to strong clinical oncology volume, Guardant360 average selling price improvements, and product upgrades.
Looking ahead, Guardant Health raised its 2025 revenue guidance to $850-$860 million, slightly above the analyst consensus of $850.3 million. This projection represents a 15-16% growth compared to 2024, or 19-20% when excluding non-recurring revenue from 2024.
"We fired on all cylinders throughout 2024, delivering remarkable revenue growth and upgrading our products to our smart liquid biopsy platform," said Helmy Eltoukhy, co-founder and co-CEO of Guardant Health.
The company also reported progress with its Shield colorectal cancer screening test, which was selected for inclusion in the NIH Vanguard multi-cancer detection study.
Despite the positive results and raised guidance, Guardant Health’s stock declined slightly in after-hours trading. This muted reaction may be due to the significant stock price appreciation over the past year, potentially leading to elevated investor expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.